Allergan to Report Fourth Quarter and Full-Year 2015 Earnings and Host Conference Call and Webcast

-- Company to Provide Full Year 2016 Revenue and Certain Additional Financial Metrics Guidance --

Jan 20, 2016, 08:00 ET from Allergan plc

DUBLIN, Jan. 20, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it intends to release fourth quarter and full-year 2015 financial results on Monday, February 22, 2016, prior to the open of the U.S. financial markets. The Company will also provide revenue and certain additional financial metrics guidance for full-year 2016.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time on Monday, February 22, 2016 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the Conference ID number is 9887081.

A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 11:30 PM Eastern Time on March 7, 2016. The replay may be accessed by dialing (855) 859-2056 and entering the Conference ID number 9887081.  From international locations, the replay may be accessed by dialing (404) 537-3406 and entering the same Conference ID number. To access the webcast, go to Allergan's Investor Relations Web site at http://ir.allergan.com. A replay of the webcast will also be available.

About Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the risks associated with acquisition transactions; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (such periodic public filings having been filed under the "Actavis plc" name) and from time to time in Allergan's other investor communications. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:     

Investors:
Lisa DeFrancesco
(862) 261-7152

Media:
Mark Marmur
(862) 261-7558

SOURCE Allergan plc



RELATED LINKS

http://www.allergan.com